Amarna's next-generation viral vector platform promises to transform treatment across many disease areas

Amarna Therapeutics, founded in 2008, is a privately held Biotech company that developed the SVac viral gene delivery vector platform, the key to the success of next stage gene and immune-therapies. SVac is safe, highly efficient, non-immunogenic and vector particles can be produced cost effectively in our SuperVero packaging cell line.

Because of its safety, efficacy and non-immunogenicity in humans our SVac platform has highly promising qualities for treating the major diseases of our time, creating opportunities to serve the major pharmaceutical markets.

Quotes